Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M

2 weeks ago 13

MarketBeat

Thu, April 16, 2026 astatine 8:09 AM CDT 5 min read

Altimmune logo

All AGM proposals approved: Shareholders elected the company's 9 manager nominees to one-year presumption and approved each point presented astatine the virtual yearly meeting.
Capital operation increased: Stockholders approved amending the certificate of incorporation to rise authorized communal shares from 200 cardinal to 400 million and expanded the 2019 Employee Stock Purchase Plan reserve from 403,500 to 1,108,827 shares.
Governance items passed: Ratification of Ernst & Young arsenic autarkic auditor and an advisory support of enforcement compensation were approved, with last voting results to beryllium filed with the SEC.
Interested successful Altimmune, Inc.? Here are 5 stocks we similar better.

MarketBeat Week successful Review – 11/4 - 11/8

Altimmune (NASDAQ:ALT) shareholders approved each proposals presented astatine the company’s virtual yearly gathering connected April 16, 2026, including the predetermination of 9 directors and amendments that grow the company’s authorized communal banal and worker banal acquisition program stock reserve.

Jerome Durso, Chairman of the Board, called the gathering to bid and said the institution was hosting the yearly gathering virtually to “be much inclusive and scope a greater fig of our shareholders via the web portal.” Durso said the gathering was held successful accordance with the company’s bylaws and Delaware law, and that the ceremonial concern was described successful the announcement and proxy connection mailed connected oregon astir March 19, 2026, to stockholders of grounds arsenic of March 13, 2026.

→ 5 Space Stocks Already Climbing Ahead of the SpaceX IPO

How Altimmune Could Grab a Big Chunk of the GLP-1 Market

The company’s directors and officers successful attendance were introduced, including extracurricular directors John M. Gill, Philip Hodges, Diane K. Jorkasky, Teri Lawver, Wayne Pisano, Mitchel Sayare, Klaus O. Schafer, and Catherine Angell Sohn, with Pisano serving arsenic Lead Independent Director. Officers introduced included Durso (also serving arsenic President and Chief Executive Officer), Greg Weaver (Chief Financial Officer), Scot Roberts (Chief Scientific Officer), Christophe Arbet-Engels (Chief Medical Officer), and Linda M. Richardson (Chief Commercial Officer).

Ernst & Young was represented by Anne V. Kroon, and extracurricular ineligible counsel Joseph C. Theis Jr. of Goodwin Procter besides attended. Robin E. Abrams, Chief Legal Officer and Corporate Secretary, recorded the minutes.

→ This New ETF Aims to Capitalize connected Surging AI Memory Chip Demand